June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Corneal collagen cross-linking for progressive keratoconus in patients 9 to 14 years old
Author Affiliations & Notes
  • Fernando Plazzi Palis
    Instituto de Olhos de Goiania, Goiania, Brazil
  • Belquiz A Nassaralla
    Instituto de Olhos de Goiania, Goiania, Brazil
  • Luis Gambi Deienno
    Instituto de Olhos de Goiania, Goiania, Brazil
  • Arthur Amaral Nassaralla
    Instituto de Olhos de Goiania, Goiania, Brazil
  • Footnotes
    Commercial Relationships Fernando Palis, None; Belquiz Nassaralla, None; Luis Deienno, None; Arthur Nassaralla, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3010. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fernando Plazzi Palis, Belquiz A Nassaralla, Luis Gambi Deienno, Arthur Amaral Nassaralla, none; Corneal collagen cross-linking for progressive keratoconus in patients 9 to 14 years old. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3010.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the safety and efficacy of corneal collagen cross-linking (CXL) for progressive keratoconus in patients 9 to 14 years old

 
Methods
 

Sixteen eyes of eleven patients (8 male and 3 female) with progressive keratoconus, underwent epithelium-off CXL according to the standard Dresden protocol. Mean follow-up was 26 months (range, 12 to 60 months). Pre- and postoperative examinations included: uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), corneal topography, refraction, corneal pachymetry, and endothelium cell count

 
Results
 

At the last follow-up visit, BSCVA improved by at least one Snellen line in 4 eyes (25%) and remained stable in 10 eyes (62.5%). Two eyes (12.5%) in habitual eye rubbers, required a re-treatment due to keratoconus progression, 15 and 28 months after first CXL. Manifest refraction and endothelium cell count remained stable. Corneal thickness decreased at the first postoperative month with gradual return to preoperative values. Topographic results showed statistically significant improvement in maximum K readings up to two years after CXL. However, it lost significance over time. No intraoperative complications were observed. Two eyes (12.5%) presented grade one haze, which regressed after a month of topical steroid therapy.<br />

 
Conclusions
 

In this study of selected patients 9 to 14 years old, CXL was a safe and effective option for the treatment of progressive keratoconus. However, the effect of arrest of disease progression may not be as long lasting as in adults.<br />

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×